These deletions have variable breakpoints, may span several megabases and often include sequences from both chromosomes 9 and 22. The deletion seems to occur at the time of formation of the Ph translocation and is associated with a more rapid disease progression and shorter survival. Patients with a deletion in der(9) respond poorly to conventional CML therapy, such as interferon a. The response rates to the novel BCR-ABL inhibitor, imatinib mesylate, are better, but still the frequency of complete haematological or cytogenetic responses are lower in patients carrying deletions compared to patients without deletions. 3 Despite the high efficacy of imatinib as a frontline therapy for CML, allogeneic stem cell transplantation (SCT) is still regarded as the only way of achieving permanent cure from CML. The influence of der(9) deletions on allogeneic SCT outcome for CML has not been studied to date. We therefore determined the frequency of der(9) deletions in a cohort of 119 Finnish adult CML patients who underwent allogeneic SCT and assessed the influence of deletion status on SCT outcome. The studied patients received allogeneic SCT from an HLA-identical sibling donor or an HLA-matched unrelated donor at the Helsinki University Central Hospital between January 1990 and September 2003.
A total of 110 patients showed the classical t(9;22) translocation. Eight patients had a variant translocation and one patient had a Ph-negative, BCR-ABL-positive disease. Fluorescence in situ hybridization (FISH) using the LSI s BCR-ABL Dual Color, Dual Fusion Translocation Probe (Vysis, Downers Grove, IL, USA) was performed to detect deletions in der(9). Relapse was defined as either a haematological or a cytogenetic (G-banding or FISH) relapse.
Differences in baseline or pretransplant characteristics were assessed with Fisher's exact and Mann-Whitney U-tests. All survival calculations were based on Kaplan-Meier estimates and significance was tested with the log-rank test. Survival data from the two groups of patients were also used for constructing a Cox proportional hazard model. Variables considered were der(9) deletion status, age at the time of transplantation, patient sex, percentage of blasts in peripheral blood and platelet count at the time of diagnosis, donor-recipient sex mismatch (female to male), donor type (sibling or matched unrelated), disease stage at the time of transplantation and time from diagnosis to transplantation. Only the last three variables were significant at Po0.20 level in univariate analysis and were included in the multivariate analysis along with the deletion status. A backward stepping procedure was used to derive the most significant model. The hazard ratio of the deletion status as a univariate analysis was compared to the hazard ratios following adjustment for the most significant model. The EBMT (European Group for Blood and Marrow Transplantation) prognostic score, which was used for assessing risk associated with SCT, was calculated as described. 4 Greater score values denote to greater transplant-related mortality and shorter survival after SCT. All calculations were made with the SPSS 11.0 software (SPSS Inc., Chicago, IL, USA).
Deletions in der(9) were found in 18 patients (15%), which is in line with previous data. 5, 6 In 11 patients, the deletions extended both to 5 0 ABL and 3 0 BCR sequences, which was observed as the lack of both red 5 0 ABL and green 3 0 BCR signals in der(9). The deletion of 5 0 ABL region only was seen in six patients and the rare deletion of 3 0 BCR sequence alone was detected in one patient. In each patient with a deletion in der(9), the deletion could be seen in every Ph-positive metaphase. If a relapse sample was available for FISH studies, it gave congruent results with the diagnostic or pretransplantation sample. These findings confirm that deletion is probably not related to disease progression.
We did not observe deletions in any of the nine patients with variant translocation. Deletions have previously been found to occur with greater frequency (40%) in CML patients with variant translocations 2,5-7 and conversely, 15-20% patients with deletions also have a variant translocation. 6 This has been regarded as the explanation for the contradictory results obtained from survival analysis. 7 Recently, deletions in der(9) were observed in FISH deletion negative cases with quantitative PCR and we cannot exclude small deletions detectable only with PCR. 8 The lack of variant translocations in patients with deletions in our material could be a chance finding, as the expected number of such patients was only 4. On the other hand, it could reflect a real and intriguing difference in the genetic background of CML. However, more studies are needed to resolve this issue.
There were no clinically significant differences at the time of diagnosis in patients with or without deletions. Prior to transplantation, the SCT outcome-related prognostic variables, such as the EBMT prognostic score, were evenly distributed between patients with or without deletions. However, there was a clear tendency toward poorer cytogenetic response to an interferon-a-containing therapy in patients with deletions, possibly reflecting the adverse outcome of these patients with conventional CML therapy. Patients with deletions also tended to be at more advanced stages of CML at the time of transplantation, in line with the published data on more rapid disease progression of these patients (Table 1) .
After transplantation, there were no differences in the incidence of acute or chronic graft vs host disease. The total relapse rate during follow-up was 17% in patients with deletions and 22% in patients without deletions (P ¼ 0.76) ( Table 1 ). In accord, the Kaplan-Meier outcome estimates for overall survival (Figure 1a) , transplant-related mortality (Figure 1b) , leukaemiafree survival (Figure 1c ) and cumulative relapse rate (Figure 1d ) were almost identical in the deletion and no-deletion groups. Multivariate analysis with a backward stepping model and using known factors associated with SCT outcome (overall survival) resulted in the elimination of the deletion status at the first step indicating that it had the least amount of impact on survival in the model. When the deletion status was forced in the multivariate model along with significant prognostic factors (donor type, disease stage at the time of transplantation and time from diagnosis to transplantation), the adjusted hazard ratio for deletion status was 0.75 (95% confidence interval 0.31-1.83) as compared to univariate hazard ratio of 0.85 (0.36-2.04). After a median follow-up of 28-39 months for evaluable patients, the relapse rate, overall and leukaemia-free survival and transplant-related mortality were similar in patients with and without deletions. It is unlikely that a longer follow-up time would alter the results, as 87% of the post-transplant events (relapse or transplant-related deaths) occurred within 2 years of transplantation. However, larger multicentre studies with sufficient power for detailed multivariate analysis are required to confirm our single-centre experience.
Previously, in a smaller cohort, rate of relapse after allogeneic SCT was higher in patients with deletions than in patients without deletions. 6 However, the rate of relapse in the nondeleted patients was exceptionally low (4%) indicating a possible bias in the distribution of prognostic variables or a too short follow-up time.
It is possible that the identical transplant outcome curves between the deleted and nondeleted patients are due to selection bias: those deletion patients progressing soon after diagnosis often do not end up in allogeneic transplantation. However, this is unlikely as the frequency of deletion patients (15%) is similar to earlier reports.
In conclusion, the poor prognosis associated with der(9) deletions can be reversed with allografting. We therefore propose that for newly diagnosed patients, the deletion status combined with a transplant-related prognostic score, such as the EBMT score, could be an important criteria when making the decision for allogeneic transplantation. Some cytogenetic response is defined as less than 100% Ph-positive mitoses in patients with interferon-a containing therapy.
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